{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-23-000094","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.564324+00:00","generated_at":"2026-06-13T02:55:21.958360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M","bullets":["Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).","Net loss of $5.1M, improvement of $9.7M vs Q2 2022; EPS loss $0.11 vs $0.32.","Gross margin 76.4%, up 130 bps YoY; adjusted EBITDA positive $8.0M, up from -$3.2M.","FY 2023 guidance: revenue $392M-$395M (19-20% growth), adjusted EBITDA ~$12M positive.","Adjusted loss per share guided at $0.92-$0.94 for full year 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-23-000094","json":"https://secwatch.observer/filing/0001323885-23-000094.json","markdown":"https://secwatch.observer/filing/0001323885-23-000094.md","text":"https://secwatch.observer/filing/0001323885-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000094/0001323885-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000094/atrc-20230725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:55:21.958360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99c69f312170235019196811b4c244bc02cb7d2c","claim":"AtriCure, Inc. reported the second quarter ended June 30, 2023 results: revenue $100.9 million, net income Net loss of $5.1 million, EPS $0.11. Guidance reaffirmed.","evidence_excerpt":"in any such filing or document. --- EX-99.1 (EX-99.1) --- For immediate release July 25, 2023 AtriCure Reports Second Quarter 2023 Financial Results • Worldwide revenue of $100.9 million – an increase of 19.4% year over year • U.S. revenue of $84.9 million – an increase of 19.1% year over year • International revenue of $16.0 million – an increase of 20.7% year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388523000094/0001323885-23-000094-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$100.9 million"},{"label":"Net income","value":"Net loss of $5.1 million"},{"label":"EPS","value":"$0.11"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}